Utilisation des substances psychédéliques en thérapeutique et « auto-expérimentation » Docteur Christian SUEUR Colloque ATHS, 4 octobre 2019, Biarritz Le 14 mai dernier, est paru sur le site Vice.com, un article signé de Shayla Love, intitulé « The Ethics of Taking the Drugs You Study. Should psychedelic scientists trip on the drugs they research ? ».[1] Cette question pause la question, tant éthique que technique, de la nécessaire juxtaposition, lorsque l’on envisage la mise en place de thérapies psychédéliques, des apports récents de la neurobiologie éclairant le mode d’action cérébral des substances psychédéliques, et de la connaissance des effets psychiques de ces substances, grâce à l’auto-expérimentation des effets de [...]
Lire la suiteScientists mass-produce 'magic mushroom' active ingredient from bacteria The study shows that psilocybin can be produced in a sustainable manner. https://www.zmescience.com/medicine/scientists-mass-produce-magic-mushroom-active-ingredient-from-bacteria/ byTibi Puiu October 3, 2019 Psilocybin, the active psychoactive compound found in specific mushrooms, is a promising drug that can be used to treat depression, anxiety, addiction, and post-traumatic stress disorder. Looking towards the future, researchers at Miami University have used genetic engineering to coax harmless E. coli bacteria to produce psilocybin. Psilocybe semilanceata. Credit: Pixabay. The mushrooms that produce psilocybin, such as Psilocybe cubensis, are not particularly expensive or difficult to grow. However, they do take up a lot of space and require many [...]
Lire la suiteOpportunities for cannabis in supportive care in cancer Amber S. Kleckner , Ian R. Kleckner, Charles S. Kamen, Mohamedtaki A. Tejani, Michelle C. Janelsins, Gary R. Morrow and Luke J. Peppone Therapeutic Advances in Medical Oncology, 2019, Vol. 11, 1–29 Doi : 10.1177/1758835919866362 Abstract Cannabis has the potential to modulate some of the most common and debilitating symptoms of cancer and its treatments, including nausea and vomiting, loss of appetite, and pain. However, the dearth of scientific evidence for the effectiveness of cannabis in treating these symptoms in patients with cancer poses a challenge to clinicians in discussing this option with their patients. A review [...]
Lire la suiteDon’t Fear the Reefer—Evidence Mounts for Plant-Based Cannabidiol as Treatment for Epilepsy - Commentary M. Scott Perry Epilepsy Currents, 2019, Vol. 19, (2), 93-95 DOI: 10.1177/1535759719835671 Effect of Cannabidiol on Drop Seizures in the Lennox-Gastaut Syndrome Devinsky O, Patel AD, Cross JH, et al; GWPCARE3 Study Group. N Engl J Med, 2018, 378, 1888-1897. Background : Cannabidiol has been used for treatment-resistant seizures in patients with severe early-onset epilepsy. We investigated the efficacy and safety of cannabidiol added to a regimen of conventional antiepileptic medication to treat drop seizures in patients with the Lennox-Gastaut syndrome, a severe developmental epileptic encephalopathy. Methods : In this double-blind, placebo-controlled trial conducted [...]
Lire la suiteDosage Related Efficacy and Tolerability of Cannabidiol in Children With Treatment-Resistant Epileptic Encephalopathy : Preliminary Results of the CARE-E Study Richard J. Huntsman, Richard Tang-Wai, Jane Alcorn, Stephanie Vuong, Bryan Acton1,5, Scott Corley, Robert Laprairie, Andrew W. Lyon, Simona Meier, Darrell D. Mousseau, Doris Newmeyer, Erin Prosser-Loose, Blair Seifert, Jose Tellez-Zenteno, Linda Huh, Edward Leung and Philippe Major Frontiers in Neurology, 2019, 10:716. doi: 10.3389/fneur.2019.00716 Purpose : There is uncertainty regarding the appropriate dose of Cannabidiol (CBD) for childhood epilepsy. We present the preliminary data of seven participants from the Cannabidiol in Children with Refractory Epileptic Encephalopathy (CARE-E) study. Methods : The study is an open-label, [...]
Lire la suiteCannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. Bin Gu, Manhua Zhu, Madison R. Glass, Marie Rougié, Viktoriya D. Nikolova, Sheryl S. Moy, Paul R. Carney, and Benjamin D. Philpot Journal of Clinical Investigation, 2019 Sep 10, pii: 130419. doi : 10.1172/JCI130419 PMID : 31503547 Abstract Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and [...]
Lire la suiteIACM-Bulletin du 27 Septembre 2019 Science/Homme: La consommation de cannabis est associée à une réduction des infections due à une maladie bactérienne fréquemment attrapée dans les hôpitaux Science/Homme: La capsaïcine peut être utile dans le syndrome d'hyperémèse de cannabinoïde Science/Homme: Le THC peut être utile chez les patients souffrant de douleur gériatrique En bref Un coup d'œil sur le passé Science/Homme: La consommation de cannabis est associée à une réduction des infections due à une maladie bactérienne fréquemment attrapée dans les hôpitaux Lors d’une étude portant sur 59 824 patients, la consommation de cannabis [...]
Lire la suiteEC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019 The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]
Lire la suiteA National Survey of Marijuana Use Among US Adults With Medical Conditions, 2016-2017 Hongying Dai, Kimber P. Richter JAMA Network Open, 2019, 2, (9), e1911936. doi:10.1001/jamanetworkopen.2019.11936 Abstract IMPORTANCE : The number of states legalizing marijuana for medical and recreational use is increasing. Little is known regarding how or why adults with medical conditions use it. OBJECTIVES : To report the prevalence and patterns of marijuana use among adults with and without medical conditions, overall and by sociodemographic group, and to further examine the associations between current marijuana use and the types and number of medical conditions. DESIGN, SETTING, AND PARTICIPANTS : This survey study used a probability [...]
Lire la suiteAdolescent‐onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus Grace Blest‐Hopley | Aisling O'Neill | Robin Wilson | Vincent Giampietro | David Lythgoe | Alice Egerton | Sagnik Bhattacharyya Addiction Biology, 2019, e12827, 1-11. DOI: 10.1111/adb.12827 Abstract Cannabis use has been associated with adverse mental health outcomes, the neurochemical underpinnings of which are poorly understood. Although preclinical evidence suggests glutamatergic dysfunction following cannabis exposure in several brain regions including the hippocampus, evidence from human studies have been inconsistent. We investigated the effect of persistent cannabis use on the brain levels of N‐acetyl aspartate (NAA) and myo-inositol, [...]
Lire la suite